1. Home
  2. NCA vs XOMA Comparison

NCA vs XOMA Comparison

Compare NCA & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NCA
  • XOMA
  • Stock Information
  • Founded
  • NCA 1987
  • XOMA 1981
  • Country
  • NCA United States
  • XOMA United States
  • Employees
  • NCA N/A
  • XOMA N/A
  • Industry
  • NCA Investment Managers
  • XOMA Biotechnology: Pharmaceutical Preparations
  • Sector
  • NCA Finance
  • XOMA Health Care
  • Exchange
  • NCA Nasdaq
  • XOMA Nasdaq
  • Market Cap
  • NCA N/A
  • XOMA 250.1M
  • IPO Year
  • NCA N/A
  • XOMA N/A
  • Fundamental
  • Price
  • NCA $8.64
  • XOMA $19.30
  • Analyst Decision
  • NCA
  • XOMA Strong Buy
  • Analyst Count
  • NCA 0
  • XOMA 2
  • Target Price
  • NCA N/A
  • XOMA $72.00
  • AVG Volume (30 Days)
  • NCA 59.6K
  • XOMA 30.1K
  • Earning Date
  • NCA 01-01-0001
  • XOMA 03-17-2025
  • Dividend Yield
  • NCA 3.92%
  • XOMA N/A
  • EPS Growth
  • NCA N/A
  • XOMA N/A
  • EPS
  • NCA N/A
  • XOMA N/A
  • Revenue
  • NCA N/A
  • XOMA $28,487,000.00
  • Revenue This Year
  • NCA N/A
  • XOMA $29.60
  • Revenue Next Year
  • NCA N/A
  • XOMA $34.18
  • P/E Ratio
  • NCA N/A
  • XOMA N/A
  • Revenue Growth
  • NCA N/A
  • XOMA 498.72
  • 52 Week Low
  • NCA $7.77
  • XOMA $19.12
  • 52 Week High
  • NCA $9.12
  • XOMA $35.00
  • Technical
  • Relative Strength Index (RSI)
  • NCA 49.54
  • XOMA 27.79
  • Support Level
  • NCA $8.62
  • XOMA $20.45
  • Resistance Level
  • NCA $8.75
  • XOMA $21.45
  • Average True Range (ATR)
  • NCA 0.08
  • XOMA 0.80
  • MACD
  • NCA -0.01
  • XOMA 0.05
  • Stochastic Oscillator
  • NCA 52.17
  • XOMA 6.49

About XOMA XOMA Corporation

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.

Share on Social Networks: